Correlation Study Of DNA-PKCs And Osteosarcoma Chemotherapy Resistance

ObjectiveStudy of human osteosarcoma U-2 OS cell line chemotherapy and the expression of DNA-PKCs correlation between the monitoring of human osteosarcoma U-2 OS cells with chemotherapy drug cisplatin (DDP), DNA-PKCs inhibitor wortmannin and combination cell activity after changes in the expression and DNA-PKCs differences of DNA-PKCs inhibitor wortmannin in human osteosarcoma chemotherapy significance, and the application of DNA-PKCs inhibitors such as wortmannin treatment of human osteosarcoma U-2 OS cells to chemotherapeutic drug sensitivity.MethodColorimetric method using thiazole salt (MTT) test and compare human osteosarcoma U-2 OS cell lines to cisplatin (DDP), DNA-PKCs inhibitors wortmannin and combination of drugs sensitivity, use of medication inverted microscope before and after intervention cell General gross morphological changes; using Western blot (Western blot) to detect DNA-PKCs protein in human osteosarcoma U-2 OS cells with chemotherapy drug cisplatin (DDP), DDP+wortmannin cells were cultured after 48 hours.ResultIn this study, MTT assay cells to different concentrations of DDP, Wortmannin and DDP+Wortmannin (two with pre-concentration gradient change) intervention in the three groups were human osteosarcoma U-2 OS cells after 48h, each of the cells proliferation inhibition in a dose-dependent.OD was significantly reduced compared with the control group there were significant differences (P<0.05).The three groups inhibited the cell proliferation level of DDP+Wortmannin> DDP> Wortmannin, both combined with cisplatin and Wortmannin induced by human osteosarcoma U-2 OS cells inhibit the proliferation of tumor was significantly higher than the other two groups, DDP, Wortmannin and DDP+Wortmannin were compared among all groups or the two samples both t test (P<0.05). Cell activity of the previous step results, select the appropriate concentration of DDP, DDP+Wortmannin two groups were treated human osteosarcoma U2-OS cells after 48 hours, using Western blot (Western blot) to detect protein expression of DNA-PKCs.The results two groups of cells within the DNA-PKcs protein were reduced, especially in the latter significantly, and the control group (P<0.01) between the two groups t test.Conclusion1.The results show that DNA-PKCs inhibitor Wortmannin can enhance cisplatin anti-osteosarcoma cells, enhances cisplatin-induced apoptosis of osteosarcoma cells, Wortmannin in human osteosarcoma U-2 OS cells during cisplatin has played a role in sensitizing2. At the molecular level of human osteosarcoma U-2 OS cells resistant mechanisms of cisplatin.Tips osteosarcoma cells resistant to chemotherapy may be the high DNA-PKcs expression, and further verified the expression of DNA-PKCs may be associated with the prognosis of osteosarcoma of view.3.This sdudy improve the chemotherapy of osteosarcoma to provide a new approach for clinical reversal of chemotherapy resistance in osteosarcoma laid the foundation for further study, and expected to osteosarcoma chemotherapy Wortmannin as a new drug,and improve the comprehensive tre-atment of osteosarcoma efficiency and quality of life of patients with osteosa-rcoma.